Fredun Pharmaceuticals Ltd vs Rubicon Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 11, 2026

Key Highlights

The Latest Trading Price of Fredun Pharmaceuticals Ltd is ₹ 2374 as of 08 May 15:30 . The P/E Ratio of Fredun Pharmaceuticals Ltd changed from 16 on March 2025 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Rubicon Research Ltd changed from 0 on March 2025 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years The Market Cap of Fredun Pharmaceuticals Ltd changed from ₹ 315.67 crore on March 2025 to ₹ 0 crore on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Rubicon Research Ltd changed from ₹ 0 crore on March 2025 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years The revenue of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 160.92 crore as compare to the Sep '25 revenue of ₹ 145.29 crore. This represent the growth of 10.76% The revenue of Rubicon Research Ltd for the Dec '25 is ₹ 479.32 crore as compare to the Sep '25 revenue of ₹ 412.72 crore. This represent the growth of 16.14% The ebitda of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 22.33 crore. This represent the growth of 17.96% The ebitda of Rubicon Research Ltd for the Dec '25 is ₹ 111.91 crore as compare to the Sep '25 ebitda of ₹ 94.99 crore. This represent the growth of 17.81% The net profit of Fredun Pharmaceuticals Ltd changed from ₹ 13.74 crore to ₹ 10.48 crore over 5 quarters. This represents a CAGR of -19.48% The net profit of Rubicon Research Ltd changed from ₹ 25.57 crore to ₹ 72.8 crore over 7 quarters. This represents a CAGR of 81.83% The Dividend Payout of Fredun Pharmaceuticals Ltd changed from 13.9 % on March 2021 to 1.59 % on March 2025 . This represents a CAGR of -35.18% over 5 yearsThe Dividend Payout of Rubicon Research Ltd changed from -1.5 % on March 2023 to 0.18 % on March 2025 . This represents a CAGR of NaN% over 3 years .

About Fredun Pharmaceuticals Ltd

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94.
The Company was promoted by Nariman Medhora and Daulat N Medhora.
The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations.
Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy.
The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products.

About Rubicon Research Ltd

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.
The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'.
A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products.

FAQs for the comparison of Fredun Pharmaceuticals Ltd and Rubicon Research Ltd

Which company has a larger market capitalization, Fredun Pharmaceuticals Ltd or Rubicon Research Ltd?

Market cap of Fredun Pharmaceuticals Ltd is 1,309 Cr while Market cap of Rubicon Research Ltd is 15,728 Cr

What are the key factors driving the stock performance of Fredun Pharmaceuticals Ltd and Rubicon Research Ltd?

The stock performance of Fredun Pharmaceuticals Ltd and Rubicon Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fredun Pharmaceuticals Ltd and Rubicon Research Ltd?

As of May 11, 2026, the Fredun Pharmaceuticals Ltd stock price is INR ₹2374.95. On the other hand, Rubicon Research Ltd stock price is INR ₹954.7.

How do dividend payouts of Fredun Pharmaceuticals Ltd and Rubicon Research Ltd compare?

To compare the dividend payouts of Fredun Pharmaceuticals Ltd and Rubicon Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.